Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis GCL2505 + inulin
- Development stage
- Preclinical
- Lead developer
- Ezaki Glico
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis GCL2505 + inulin is a synbiotic combination consisting of the probiotic bacterial strain *Bifidobacterium animalis* subsp. *lactis* GCL2505 and the prebiotic dietary fiber inulin. Developed by Ezaki Glico, the GCL2505 strain is a human-derived probiotic known for its high survival rate and proliferative capacity in the intestinal tract. The combination works by modulating the gut microbiota, significantly increasing total bifidobacteria counts and promoting the production of short-chain fatty acids (SCFAs), particularly acetate. These metabolites interact with host receptors such as GPR43 to influence energy metabolism and lipid profiles. Clinical studies in Japanese adults have demonstrated its efficacy in reducing visceral fat area, increasing resting energy expenditure, improving defecation frequency, and enhancing cognitive and vascular endothelial functions.
- Brand names
- BifiX
- Other names
- B. lactis GCL2505 + inulinBifidobacterium animalis ssp. lactis GCL2505 + inulin
02
Targets
FFAR2
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis GCL2505 + inulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis GCL2505 + inulin.